Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 1/20 | 0.40 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | APAF1 | O14727 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GRK6 | P43250 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5726677 | 0.82 | CNR2 (0.40) | SIRT2CNR2ALDH1A1HTTTNF | |
| SCHEMBL4861460 | 0.71 | MAPK1 (0.43) | AGTR1AGTR2ALDH1A1TP53KDM4E | |
| SCHEMBL5727260 | 0.70 | KDM4E (0.39) | ALDH1A1TNFLMNATP53KDM4E | |
| SCHEMBL9277280 | 0.70 | SIRT2 (0.43) | AGTR1AGTR2SIRT2CNR2ALDH1A1 | |
| SCHEMBL5726908 | 0.69 | HPGD (0.43) | ALDH1A1TNFL3MBTL1KDM4EAPAF1 | |
| SCHEMBL12926023 | 0.67 | KMT2A (0.46) | ALDH1A1TP53KDM4EGAAMAPT | |
| SCHEMBL9310663 | 0.67 | GPR84 (0.43) | ALDH1A1HTTLMNATP53KDM4E | |
| SCHEMBL28937824 | 0.67 | ALDH1A1 (0.44) | ALDH1A1HTTL3MBTL1LMNAGAA | |
| SCHEMBL26375451 | 0.67 | TP53 (0.46) | ALDH1A1LMNATP53KDM4EGAA | |
| SCHEMBL20503315 | 0.67 | NPSR1 (0.50) | ALDH1A1LMNAMEN1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080262066-A1 | Azole Derivatives as Cannabinoid CB1 Receptor Antagonists | GREEN CROSS CORPORATION (KR) | 2008-10-23 | — | — | US | disclosed |
| WO-2008105607-A1 | HETEROARYL-IMIDAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | GREEN CROSS CORPORATION (KR) | 2008-09-04 | — | — | WO | disclosed |
| US-20080207704-A1 | HETEROARYL-IMIDAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | THE GREEN CROSS CORPORATION (KR) | 2008-08-28 | — | — | US | disclosed |
| US-20080207705-A1 | Heteroaryl-Imidazole Derivatives as Cannabinoid CB1 Receptor Antagonists | GREEN CROSS CORPORATION (KR) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207704-A1 | HETEROARYL-IMIDAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | CNR2, CNR1, GPR119 | AGTR1 130/4885AGTR2 87/4885SIRT2 517/4885 |
| US-20080207705-A1 | Heteroaryl-Imidazole Derivatives as Cannabinoid CB1 Receptor Antagonists | CNR2, CNR1, GPR119 | AGTR1 123/4885AGTR2 94/4885SIRT2 740/4885 |
| US-20080262066-A1 | Azole Derivatives as Cannabinoid CB1 Receptor Antagonists | CNR1, CNR2, GPR119 | AGTR1 24/4885AGTR2 21/4885SIRT2 1334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.